Analyst Michael Ulz works at MORGAN STANLEY and is focused on the Healthcare sector with 177 price targets and ratings documented since 2016 spanning on 18 stocks. Analyst's average stock valuation to be materialised ratio is 47.9% with an average time for price targets to be met of 223.28 days.
Most recent stock forecast was given on BPMC, Blueprint Medicines Corporation at 02-Nov-2022.
Michael Ulz best performing recommendations are on NRIX (NURIX THERAPEUTICS INC.).
The best stock recommendation documented was for FATE (FATE THERAPEUTICS, INC) at 12/16/2021. The price target of $62 was fulfilled within 5 days with a profit of $10.37 (20.09%) receiving and performance score of 40.17.
Average potential price target upside